Fate Therapeutics (FATE) Tops Q4 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Waste stocks ride AI and healthcare boom as CLH surges 27%
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT